A quartet of heart doctors are trying to resuscitate health-monitoring tech outfit AliveCor's antitrust lawsuit regarding the Apple Watch, by arguing changes made to the iMaker's gadget"resulted in a loss of access to a potentially life-saving product.
The specialists said those sporadic readings may cause software to miss signs of a forthcoming stroke, which would be bad, and continuous monitoring is preferred yet no longer possible. "From a medical point of view, IRN is inferior when it comes to medical monitoring," wrote the doctors."IRN only sporadically measures a user's heart rhythm; and critically, unlike the AliveCor product, Apple's feature is not FDA cleared for users with Afib ."
They continued:"Moreover, antitrust precedent is clear that the purported benefits of Apple’s product change still must be evaluated against its clear anticompetitive effects."It's worth noting two of the four cardiac specialists who authored the brief are directly affiliated with AliveCor – one on its clinical advisory board, and another sits on the board of directors.